Research proposes that mitigating the elevation of TNF-α through strategies such as dexmedetomidine [PMID: 37550504], inhibiting TNF-α release via the mmu_circ_0001442/miR-125a-3p/NUFIP2 pathway [PMID: 37550899], decreasing TNF-α expression using probiotics that curb gut inflammation [PMID: 37571319], and reducing TNF-α alongside other inflammatory markers [PMID: 37562566] can alleviate cognitive impairments. This evidence concerns the gene NUFIP2 and Cognitive impairment.